Rare Disease Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The National Organization for Rare Disorders’ campaign to get FDA to codify a flexible approach on approving orphan drugs is now bolstered by an analysis that concludes most of the agency’s approval decisions for such products already use unconventional efficacy standards.